NasdaqGS:ANIKBiotechs
Anika Therapeutics (ANIK) Q4 Profit Challenges Ongoing Unprofitability Narrative Ahead Of Q1 Earnings
Anika Therapeutics (ANIK) closed Q4 2025 with total revenue of about US$30.6 million and basic EPS of US$0.13, setting the stage for Q1 2026 after a year in which trailing twelve month revenue reached roughly US$112.8 million and basic EPS on that basis was a loss of US$0.70. Over recent quarters the company has seen revenue move from US$26.2 million in Q1 2025 to US$30.6 million in Q4 2025, while basic EPS shifted from a loss of US$0.28 to a profit of US$0.13. This highlights a quarter that...